THE MCMANUS GROUP for DENDREON PHARMACEUTICALS LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 15, 2020 | $30,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Aug 6, 2020 | $30,000 | Replaced |
| 2nd Quarter - Amendment | Jan 11, 2022 | $30,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 and S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019. H.R. 748, the CARES Act. Coronavirus relief waivers.
Foreign entity interest: Dendreon is a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL BRYAN CRONAN | — |
| JOHN MCMANUS | LA, Bill Thomas. Staff Director, W&M Health Subcommittee |
| ALANNA TEMME | LD, Rep. Jon Porter |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.